Perspective Therapeutics (NYSEAMERICAN:CATX) Director Purchases $19,950.00 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Lori Woods acquired 23,750 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was acquired at an average cost of $0.84 per share, for a total transaction of $19,950.00. Following the completion of the purchase, the director directly owned 28,557 shares of the company’s stock, valued at approximately $23,987.88. This represents a 494.07% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN:CATX opened at $0.94 on Monday. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The stock’s fifty day simple moving average is $2.11 and its two-hundred day simple moving average is $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Research analysts expect that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently modified their holdings of CATX. Provenance Wealth Advisors LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at $44,000. Auctus Advisors LLC raised its holdings in shares of Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after acquiring an additional 17,015 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock worth $168,000 after purchasing an additional 21,150 shares during the period. Quantinno Capital Management LP bought a new stake in Perspective Therapeutics during the 1st quarter valued at approximately $273,000. Finally, Taylor & Morgan Wealth Management LLC raised its holdings in Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock worth $225,000 after purchasing an additional 37,000 shares in the last quarter. Institutional investors own 54.66% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on CATX shares. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a research note on Monday, October 26th. Piper Sandler reduced their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. Royal Bank Of Canada cut shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $14.00 to $4.00 in a report on Monday, October 26th. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, Perspective Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $10.10.

Get Our Latest Stock Report on CATX

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Recommended Stories

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.